Quantcast

Latest Regeneron Stories

2014-07-18 16:23:22

TARRYTOWN, N.Y., July 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2014 financial and operating results on Tuesday, August 5, 2014, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International). A link to the...

2014-07-18 08:23:16

TARRYTOWN, N.Y., July 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the Phase 3 VIVID-DME trial of EYLEA(®) (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser...

2014-07-09 16:28:51

Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine TARRYTOWN, N.Y. and PARIS, July 9, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. All doses of dupilumab met the primary endpoint...

2014-06-27 08:24:46

TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to diabetic macular edema (DME). The decision of the European Commission is expected in the second half of 2014. "Diabetes is a growing health concern worldwide and this milestone brings us...

2014-06-12 00:22:01

Both doses of investigational drug sarilumab met all three co-primary endpoints PARIS and TARRYTOWN, N.Y., June 12, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis (RA) patients who were inadequate responders to methotrexate (MTX) therapy. New data presented at the meeting showed that sarilumab increased major clinical...

2014-06-11 04:21:59

TARRYTOWN, N.Y., June 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA(®) (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO). The EMA submission is based on the positive Phase 3 VIBRANT trial, a double-masked,...

2014-06-02 16:27:58

10 Promising Early-Career Biomedical Researchers Recognized TARRYTOWN, N.Y., June 2, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the second annual winners of the Regeneron Prize for Creative Innovation, an award designed to acknowledge, reward, and foster talented early-career biomedical scientists. This year, Regeneron awarded $160,000 in prize money to 10 awardees and two institutions. "The Regeneron Prize for Creative Innovation identifies and...

2014-05-30 16:25:00

TARRYTOWN, N.Y., May 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the following investor conferences: -- Jefferies 2014 Global Healthcare Conference at 8:30 AM Eastern Time on Thursday, June 5, 2014 -- 2014 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc., at 10:30 AM Eastern Time on Friday June 13, 2014 The session may be accessed through the Company's web site,...

2014-05-05 08:28:53

TARRYTOWN, N.Y. and MENLO PARK, Calif., May 5, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular...

2014-05-02 12:26:46

TARRYTOWN, N.Y., May 2, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: -- Citi Biotech Virtual Conference: "What is Overlooked in Your Pipeline" at 10:00 a.m. Eastern Time on Monday, May 12, 2014 -- Bank of America Merrill Lynch 2014 Healthcare Conference at 4:40 p.m. Eastern Time (1:40 p.m. Pacific Time) on Wednesday, May 14, 2014 -- UBS Global Healthcare...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related